iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
iRhythm Technologies (NASDAQ:IRTC) will present at the 44th Annual J.P. Morgan Healthcare Conference.
Management is scheduled to present on Monday, January 12, 2026 at 8:15 a.m. PT / 11:15 a.m. ET. A live and archived webcast will be available in the Events and Presentations section of the company investor website at investors.irhythmtech.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
IRTC was up 0.46% while peers were mixed: BRKR gained 1.09%, GKOS, MASI, BIO, and GMED were modestly negative. This points to stock-specific dynamics rather than a broad Medical Devices move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 21 | Clinical data update | Positive | +4.8% | Large APHRS 2025 analysis supported Zio monitoring performance across Asian populations. |
| Nov 11 | Publication & data | Positive | +0.0% | Heart Rhythm study and AHA data highlighted benefits of long-term Zio monitoring. |
| Nov 04 | Investor conferences | Neutral | -0.3% | Outlined multiple upcoming investor conference presentations and webcast access. |
| Oct 30 | Quarterly earnings | Positive | -0.6% | Q3 2025 revenue growth, margin expansion, narrowed losses, and higher full‑year guidance. |
| Oct 16 | Earnings notice | Neutral | +0.4% | Announced timing and webcast details for upcoming Q3 2025 results call. |
Recent news has generally seen price moves aligned with the tone of announcements, with one notable divergence on strong Q3 2025 earnings where shares slipped modestly despite positive fundamentals.
Over the last few months, iRhythm reported strong Q3 2025 growth with higher guidance, supported by multiple large-scale Zio® monitoring studies and conference data in November 2025. These clinical and real‑world results reinforced the performance and generalizability of its long‑term continuous ECG monitoring platform. The company also maintained active investor outreach through several conferences. Today’s announcement of a presentation at the 44th J.P. Morgan Healthcare Conference extends that investor engagement trajectory rather than marking a new clinical or financial inflection.
Market Pulse Summary
This announcement highlights iRhythm’s participation in the influential 44th J.P. Morgan Healthcare Conference on January 12, 2026. It continues a recent pattern of active investor engagement following strong Q3 2025 growth and multiple large-scale Zio® monitoring studies. Investors may focus on any incremental detail management shares there on strategy, growth drivers, or pipeline. Key watchpoints remain execution versus raised guidance, evolving clinical evidence, and ongoing insider and regulatory disclosures.
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference.
iRhythm’s management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Events and Presentations” section of the company’s investor website at investors.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Investor Relations Contact
Stephanie Zhadkevich
investors@irhythmtech.com
Media Contact
Kassandra Perry
irhythm@highwirepr.com